<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588521</url>
  </required_header>
  <id_info>
    <org_study_id>AL-794-801</org_study_id>
    <nct_id>NCT02588521</nct_id>
  </id_info>
  <brief_title>A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, First-in-human, Study of Orally Administered AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alios Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alios Biopharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled, 4 part study will assess the safety,
      tolerability, pharmacokinetics and antiviral activity of orally administered AL-794 in
      healthy volunteers (HV).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2015</start_date>
  <completion_date type="Actual">August 14, 2017</completion_date>
  <primary_completion_date type="Actual">August 14, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Data including but not limited to tabulation of adverse events, physical exam, vital signs, 12-lead ECGs and clinical lab results</measure>
    <time_frame>Screening to Day 8 in Single Dose and Food Effect portions of the study</time_frame>
    <description>Safety data including but not limited to tabulation of adverse events, physical exam, vital signs, 12-lead ECGs and clinical lab results (including chemistry, hematology, and urinalysis).
Note that in the Multiple Ascending Dose (MAD) portion of the study, the time frame is from Screening to Day 17 (MAD) and for the Viral Challenge portion of the study the time frame is from Screening to Day 28 (Viral Challenge).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Data including but not limited to tabulation of adverse events, physical exam, vital signs, 12-lead ECGs and clinical lab results</measure>
    <time_frame>Screening to Day 17 in the Multiple Ascending Dose portion of the study</time_frame>
    <description>Safety data including but not limited to tabulation of adverse events, physical exam, vital signs, 12-lead ECGs and clinical lab results (including chemistry, hematology, and urinalysis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Data including but not limited to tabulation of adverse events, physical exam, vital signs, 12-lead ECGs and clinical lab results</measure>
    <time_frame>Screening to Day 28 in the Viral Challenge portion of the study.</time_frame>
    <description>Safety data including but not limited to tabulation of adverse events, physical exam, vital signs, 12-lead ECGs and clinical lab results (including chemistry, hematology, and urinalysis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: AL-794</measure>
    <time_frame>From baseline to Day 8 for Single Dose and Food Effect cohorts</time_frame>
    <description>Pharmacokinetic parameter of ALS-033719 and ALS-033927 (and other metabolites, if applicable) in plasma following single dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: AL-794</measure>
    <time_frame>From baseline to Day 17 for Multiple Ascending Dose Cohorts</time_frame>
    <description>Pharmacokinetic parameter of ALS-033719 and ALS-033927 (and other metabolites, if applicable) in plasma following multiple dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC: AL-794</measure>
    <time_frame>From baseline to Day 8 for Single Dose and Food Effect cohorts</time_frame>
    <description>Pharmacokinetic parameter of ALS-033719 and ALS-033927 (and other metabolites, if applicable) in plasma following single dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC: AL-794</measure>
    <time_frame>From baseline to Day 17 for Multiple Ascending Dose cohorts</time_frame>
    <description>Pharmacokinetic parameter of ALS-033719 and ALS-033927 (and other metabolites, if applicable) in plasma following multiple dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMax: Fed vs. Fasted</measure>
    <time_frame>First dose to Day 8 (Single Ascending Dose/Food Effect)</time_frame>
    <description>Comparison of Cmax after a single oral dose in HV in fasted conditions as compared with fed conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC: Fed vs. Fasted</measure>
    <time_frame>First dose to Day 8 (Single Ascending Dose/Food Effect)</time_frame>
    <description>Comparison of AUC after a single oral dose in HV in fasted conditions as compared with fed conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza Viral Load</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>AUC0-t of influenza viral load, as determined by quantitative polymerase chain reaction (PCR) assay of nasopharyngeal swab, from baseline (i.e., immediately prior to treatment onset) through checkout, Day 17, and completion of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak influenza viral load after treatment</measure>
    <time_frame>inoculation to Day 28</time_frame>
    <description>Peak influenza viral load after treatment onset, as determined by quantitative PCR assay of nasopharyngeal swab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>AL-794</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-794 administered orally in a suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Suspension vehicle alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL-794</intervention_name>
    <arm_group_label>AL-794</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo/Vehicle</intervention_name>
    <description>Suspension vehicle without active drug</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has provided written consent.

          2. In the investigator's opinion, the subject is able to understand and comply with
             protocol requirements, instructions, and protocol stated restrictions and is likely to
             complete the study as planned.

          3. Subject is in good health as deemed by the investigator, based on the findings of a
             medical evaluation including medical history, physical examination, laboratory tests
             and ECG.

          4. Male or female, 18-60 years of age (Parts 1-3). For Part 4, Males or female, 18-55
             years of age.

          5. Body mass index (BMI) 18-30kg/m2, inclusive. The minimum weight is 50 kg.

          6. A female subject is eligible to participate in this study if she is of non
             childbearing potential or postmenopausal and not receiving hormone replacement
             therapy.

          7. If male, subject is surgically sterile or practicing specific forms of birth control
             until 90 days after the end of the study.

        Exclusion Criteria:

          1. Clinically significant cardiovascular, respiratory, renal, gastrointestinal, hepatic,
             hematologic, neurologic, thyroid or any other medical illness or psychiatric disorder,
             as determined by the Investigator, and/or Sponsor's Medical Monitor.

          2. Positive screening test for hepatitis A, B, C or HIV infection.

          3. Clinically significant laboratory abnormalities or abnormalities which are deemed to
             interfere with the ability to interpret study data.

          4. Creatinine clearance of less than 60 mL/min (Cockroft Gault).

          5. Total bilirubin, ALT, AST, or Alkaline Phosphatase &gt; 1.2 X ULN.

          6. Any condition that, in the opinion of the investigator, would compromise the study's
             objectives or the well-being of the subject or prevent the subject from meeting the
             study requirements.

          7. Participation in an investigational drug trial or having received an investigational
             vaccine within 3 months prior to study medication (or inoculation for Part 4
             subjects).

          8. Clinically significant abnormal ECG findings.

          9. Clinically significant blood loss or elective blood donation of significant volume
             (i.e., &gt; 500 mL) within 90 days of first dose of study drug

         10. Heart rate, respiratory rate, temperature or blood pressure values outside of the
             normal range, per local standards.

         11. Unwilling to abstain from alcohol for 1 week before the start of admission until the
             final Completion Visit assessments.

         12. History of regular alcohol intake &gt; 14 units per week of alcohol for females and &gt; 21
             units per week for males (one unit is defined as 8 g alcohol) within 3 months of
             admission.

         13. For Parts 1-3, subjects with a history of tobacco use or use of nicotine-containing
             products within 2 weeks of the screening visit. For Part 4, subjects who have a
             significant history of any tobacco use at any time.

         14. The subject has a positive pre-study drug screen.

         15. The use of concomitant medications, including prescription, over the counter
             medications, herbal medications, inducers or inhibitors of CYP450 enzymes or drug
             transporters (including P-gp), within 14 days prior to the first dose of study
             medication, unless approved by the Sponsor's Medical Monitor. Occasional use of
             ibuprofen or acetaminophen is permitted.

         16. Exposure to more than four new investigational entities within 12 months prior to the
             first dosing day (Parts 1-3) or inoculation (Part 4).

         17. Evidence of active infection, including respiratory tract infection within 2 weeks
             prior to admission.

         18. Pregnant or nursing females, or women of childbearing potential. Men whose female
             partners are pregnant or contemplating pregnancy from the date of screening until 90
             days after end of study.

         19. Hypersensitivity to the active substances or to any of the excipients of AL-794.

         20. Unwillingness or inability to comply with the study protocol for any other reason.

         21. Part 4 ONLY: Contraindications to challenge with influenza virus or procedures related
             or influenza challenge study. For example:

               -  Subject is not sero-suitable.

               -  Immunocompromised status or diagnosis of active autoimmune disease.

               -  Known allergy to constituents of challenge virus.

               -  History of severe illness during adulthood due to a respiratory virus.

               -  Inability to tolerate repeated nasopharyngeal swabs.

               -  Abnormal pulmonary function in the opinion of the Investigator, as evidenced by
                  the responses to the respiratory screening questions and /or clinically
                  significant abnormalities in spirometry.

               -  Significant history of asthma.

               -  Any significant abnormality altering the anatomy of the nose or nasopharynx.

               -  Any clinically significant history of epistaxis.

               -  Any nasal or sinus surgery within six months of inoculation.

               -  Health care workers who are reasonably likely to come into contact with severely
                  immuno-compromised patients

               -  Presence of household member or close contact who has known immunodeficiency, is
                  receiving immunosuppressant medication, is undergoing or soon to undergo cancer
                  chemotherapy, has been diagnosed with emphysema, COPD, or other severe lung
                  disease, has received a bone marrow or solid organ transplant, resides in a
                  nursing home

               -  Evidence of vaccinations within the four weeks prior to inoculation/dosing,
                  whichever occurs first.

               -  Intention to receive any vaccination(s) before the Day 28 Follow Up Visit

               -  Prior participation in another Human Viral Challenge Study in the preceding 12
                  months taken from the date of inoculation in the previous study to the date of
                  expected inoculation in this study.

               -  Receipt of systemic glucocorticoids or systemic antiviral drugs within six months
                  prior to inoculation/dosing.

               -  Receipt of any systemic chemotherapy agent, immunoglobulins or any other
                  cytotoxic or immunosuppressive drugs at any time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Boyce</last_name>
    <role>Principal Investigator</role>
    <affiliation>HMR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research Ltd (HMR)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

